BioPharmSignal logoBioPharmSignal

Company Profile

Personalis Stock Price, News & Catalysts

Ticker:
PSNL
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

13.89 USD (-1.07%)

Close

Last updated: August 17, 2026

1.17B USD

Market cap

Why the stock is moving

As of Aug 17, 2026, PSNL closed down 1.07% at $13.89. No new same-company headline was identified in the current news window.

Company overview

Precision-Oncology Genomics

Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease.

NeXT Personal

NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track cancer recurrence from blood. Clinical use includes surveillance in lung and breast cancer. Personalis serves physicians through reimbursed clinical testing and pharmaceutical companies through translational research, clinical-trial and biomarker services.

Future catalysts

    Recent news

    1. 01

      Personalis Reports Second Quarter Results and Recent Highlights

    2. 02

      Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

    3. 03

      Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

    4. 04

      Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

    5. 05

      Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    VCYT

    Veracyte

    GH

    Guardant Health

    DCTH

    Delcath Systems

    CGON

    CG Oncology, Inc.

    ANGO

    AngioDynamics

    GOVX

    GeoVax Labs

    ACRV

    Acrivon Therapeutics

    HALO

    HALO

    Frequently Asked Questions

    What is the current stock price of Personalis (PSNL)?

    Personalis (PSNL) most recently closed at 13.89 USD, a -1.07% move versus the previous session.

    What is the market cap of Personalis (PSNL)?

    Personalis currently has a market capitalization of 1.17B USD on BioPharmSignal.

    What does Personalis do?

    Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease. NeXT Personal NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track cancer recurrence from...

    On which exchange is PSNL stock listed?

    Personalis (PSNL) is associated with NASDAQ, United States, Biopharma.

    What is Precision-Oncology?

    Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development.

    Which conditions is Personalis targeting with Precision-Oncology?

    Personalis is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.

    What is Genomics?

    Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development.

    What is Personalis?

    Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development.